BioCentury
ARTICLE | Company News

IQWiG says Xtandi has additional benefit for prostate cancer

December 3, 2013 1:45 AM UTC

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Xtandi enzalutamide from Astellas Pharma Inc. (Tokyo:4503) has additional benefit over best supportive care (BSC) to treat hor...